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Abstract
Background and Objective Spontaneous reporting sys-
tems (SRSs) remain the cornerstone of post-marketing drug
safety surveillance despite their well-known limitations.
Judicious use of other available data sources is essential to
enable better detection, strengthening and validation of
signals. In this study, we investigated the potential of
electronic healthcare records (EHRs) to be used alongside
an SRS as an independent system, with the aim of
improving signal detection.
Methods A signal detection strategy, focused on a limited
set of adverse events deemed important in pharmacovigi-
lance, was performed retrospectively in two data sources—
(1) the Exploring and Understanding Adverse Drug Reac-
tions (EU-ADR) database network and (2) the EudraVigi-
lance database—using data between 2000 and 2010. Five
events were considered for analysis: (1) acute myocardial
infarction (AMI); (2) bullous eruption; (3) hip fracture;
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Key Points
Overall, a spontaneous reporting system (SRS) is
better suited to detection of signals than an electronic
health record (EHR)-based system, especially for
certain types of reactions (rare events and those with
a high drug-attributable risk).
Use of EHRs might be justifiable in some situations
where SRSs perform poorly (e.g. outcomes with a
high background incidence), provided that the
additional costs can be taken into account.
SRSs and EHR-based signal detection systems can
be complementary, the additional value of one to the
other varying across events, as a function of the
background incidence of the event.
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(4) acute pancreatitis; and (5) upper gastrointestinal
bleeding (UGIB). Potential signals identified in each sys-
tem were verified using the current published literature.
The complementarity of the two systems to detect signals
was expressed as the percentage of the unilaterally identi-
fied signals out of the total number of confirmed signals. As
a proxy for the associated costs, the number of signals that
needed to be reviewed to detect one true signal (number
needed to detect [NND]) was calculated. The relationship
between the background frequency of the events and the
capability of each system to detect signals was also
investigated.
Results The contribution of each system to signal detec-
tion appeared to be correlated with the background inci-
dence of the events, being directly proportional to the
incidence in EU-ADR and inversely proportional in
EudraVigilance. EudraVigilance was particularly valuable
in identifying bullous eruption and acute pancreatitis (71
and 42 % of signals were correctly identified from the total
pool of known associations, respectively), while EU-ADR
was most useful in identifying hip fractures (60 %). Both
systems contributed reasonably well to identification of
signals related to UGIB (45 % in EudraVigilance, 40 % in
EU-ADR) but only fairly for signals related to AMI (25 %
in EU-ADR, 20 % in EudraVigilance). The costs associ-
ated with detection of signals were variable across events;
however, it was often more costly to detect safety signals in
EU-ADR than in EudraVigilance (median NNDs: 7 versus
5).
Conclusion An EHR-based system may have additional
value for signal detection, alongside already established
systems, especially in the presence of adverse events with a
high background incidence. While the SRS appeared to be
more cost effective overall, for some events the costs
associated with signal detection in the EHR might be
justifiable.
1 Introduction
Spontaneous reporting systems (SRSs) have long been the
foundation of post-marketing drug safety surveillance [1].
Despite their broad utilization, information found in such
systems is sometimes limited [2] and, as a consequence,
decisions based solely on data from these systems often
need to take into account significant uncertainties [3].
In many instances, it is not sufficient to use a single
source of information to understand a particular drug
safety issue [4], and there is a recognized need to put
together most, if not all, available relevant sources in an
efficient way.
Following the drug safety concerns surfacing between
2004 and 2007, many discussions started as to whether we
can have a more pro-active approach to signal detection
instead of relying on passive surveillance systems. In both
Europe and the USA, it was explored whether electronic
healthcare record (EHR) databases, which comprise
detailed data collected longitudinally and routinely in
actual care for large-scale populations [5], may be used for
post-marketing safety surveillance. EHRs have been pri-
marily used for signal evaluation studies; however, in
recent years, various projects have explored ways of using
them as an additional source for signal detection systems,
e.g. the Observational Medical Outcomes Partnership
(OMOP) [6, 7], Pharmacoepidemiological Research on
Outcomes of Therapeutics by a European Consortium
(PROTECT) [8] and exploring and understanding adverse
drug reactions (EU-ADR) [9, 10].
To date, only two studies [11, 12] have tried to combine
both sources in order to support the signal detection pro-
cess, while the majority of the available research has
focused rather on comparing the two systems in terms of
overall performance and usefulness [13–16].
The aim of this study was to investigate in which par-
ticular situations EHR-based signal detection systems may
add value to already existing SRSs, focusing on a limited
set of adverse events of considerable importance in phar-
macovigilance. To express this added value, we used per-
formance indicators, including percentages of unilaterally
identified signals and sensitivity to describe the ‘gains’, as
well as the number needed to detect (NND), for the ‘costs’
associated with signal detection.
2 Methods
2.1 Design
A signal detection strategy focused on a limited set of
adverse events was performed retrospectively in two data-
base systems—(1) EU-ADR and (2) EudraVigilance—
from 1 January 2000 to 1 January 2010. These are descri-
bed separately below. The two systems were considered
individually, and the most sound event definitions possible
and implementation of signal detection methods were taken
into account in each database independently in order to
optimize the performance of each one. In this study, we
used the term ‘signal’ to refer to a signal of disproportionate
reporting (SDR), as defined by the Council for International
Organizations of Medical Sciences (CIOMS) Working
Group VIII [1], in the context of signal detection in
EudraVigilance and equivalent to a statistically significant
drug–adverse event association that met a specific threshold
of increased risk in the context of EU-ADR. All drugs
captured in either of the two systems were considered.
Drugs not identifiable at the fifth level of the WHO
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Anatomical Therapeutic Chemical (ATC) classification
system, as well as herbal supplements, were excluded.
2.2 Events of Interest
We considered the following five events, selected from a list
of events previously identified as important on the basis of
expert judgment and predefined criteria [17]: (1) acute
myocardial infarction (AMI), (2) bullous eruption, (3) hip
fracture, (4) acute pancreatitis and (5) upper gastrointesti-
nal bleeding (UGIB). These events were chosen because of
their diversity in aetiology, background incidence and drug-
attributable risk attributes, which we considered might have
an impact on the performance of the two systems. To
investigate the possible correlation between the signal
detection performance of each system and the frequency of
the events, we ranked our events of interest according to the
empirically determined background frequency (i.e. the in-
cidence rate in the general population). These incidence
rates were derived from the EU-ADR network in order to
maintain the same base population across events, which
allowed for a more reasonable comparison [9].
2.3 The SRS: EudraVigilance
As the exemplar for an SRS, we used EudraVigilance, a
web-based information system launched in December 2001
and designed to manage information on suspected adverse
drug reactions (ADRs) that are reported for drugs licensed
in Europe. The total number of individual reports as of
December 2013 was 4.5 million, with 38 % of cases
originating from the European Union and 62 % from the
rest of the world [18].
2.3.1 Capturing Events of Interest
In EudraVigilance, suspected ADRs are coded using the
Medical Dictionary for Regulatory Activities (MedDRA),
an international medical terminology system developed
under the auspices of the International Conference on
Harmonisation (ICH) [19]. For capturing the events of
interest, we used adapted searches derived ad hoc from
standardized MedDRA queries (SMQs), [20] similar to
the approach used by Patadia et al. [16].
2.3.2 Method of Signal Detection
Signal detection in EudraVigilance was performed using
the proportional reporting ratio (PRR) method [21], pre-
viously validated in this database by Alvarez et al. [22].
Only cases received within the study period (from 1 Jan-
uary 2000 to 1 January 2010) were considered for identi-
fication of signals.
The threshold chosen to define a signal was a lower limit
of the confidence interval of the PRR greater than 1,
together with at least three cases being reported with the
investigated association [23]. No further adjustment was
done for possible confounding variables.
2.4 The EHR-Based System: EU-ADR
As the exemplar for an EHR-based system, we used EU-
ADR, a computerized system designed to detect potential
ADRs and built on a network of established databases from
various European countries [9]. Data from seven databases
in three countries (Denmark, Italy and The Netherlands)
were used in this study. EU-ADR includes both population-
based primary care databases (the Integrated Primary Care
Information [IPCI] database [The Netherlands] and Health
Search/CSD Patient and Pedianet [Italy]) and record-link-
age systems (the Aarhus University Hospital Database
[Denmark], the PHARMO Network [The Netherlands] and
the regional Italian claims databases of Lombardy and
Tuscany). The source population covered by the database
network is approximately 20 million patients. Drug expo-
sure in EU-ADR was identified from prescription or dis-
pensing data (depending on the database), using ATC
codes. Prescriptions with the same ATC code where the
start date of one prescription preceded the end date of the
other prescription were merged into a single episode of drug
use, starting at the beginning of the first prescription and
ending at the end of the last prescription. Periods of con-
comitant drug use were labelled as separate episodes. Only
current exposure (within 30 days of an event of interest)
was considered [9]. The characteristics of the EU-ADR
network have been extensively described elsewhere [9, 24].
2.4.1 Capturing Events of Interest
Definitions for each event of interest were previously
constructed by a team of experts and, on the basis of those,
queries were performed in each database in the network,
using the corresponding diagnosis coding schemes—the
International Classification of Diseases (ICD) 9th and 10th
revisions, and the International Classification of Primary
Care—supplemented with additional criteria such as labo-
ratory values and unstructured free-text searches, where
applicable. The results were subsequently pooled across all
databases [25]. The events AMI and UGIB had previously
been validated in the databases concerned [26, 27].
2.4.2 Method of Signal Detection
For EU-ADR, a signal detection method specifically
developed for EHR data was used: the Longitudinal Gamma
Poisson Shrinker (LGPS) [28]. LGPS is a cohort-based
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method, adapted from a Bayesian method (DuMouchel’s
Gamma Poisson Shrinker, designed for use in an SRS [see
the Electronic Supplementary Material]), which uses per-
son-time rather than case counts for estimation of the
expected number of events. Previous evaluation against
other signal detection methodologies showed that LGPS is
the best-performing method in this database system [29].
We applied a threshold to the LGPS risk ratio (RRLGPS) of
a lower limit of the 95 % credible interval[1 [28]. After
LGPS, we applied a second method, Longitudinal Evalu-
ation of Observational Profiles of Adverse events Related
to Drugs (LEOPARD), which adjusts for possible proto-
pathic bias and improves performance. LEOPARD is based
on comparison of rates of drug prescriptions initiated
within a fixed time window (±25 days) prior to and after
the occurrence of an event, on the basis of the assumption
that an increase in the number of prescriptions started after
an event relative to the number of prescriptions started
prior to the event is an indication of protopathic bias. From
a statistical perspective, this is a binomial test, which
compares the distributions of prescriptions across those two
time windows [28].
2.5 Verification of Signals
We reviewed the currently available literature in order to
determine which drug–adverse event associations identified
in the dataset represented already known associations. In
contrast to the approach used in previous studies, verifi-
cation was performed for all drug–event associations,
irrespective of whether a potential signal was flagged or not
by any of the signal detection methods used in either
EudraVigilance or EU-ADR.
An automatic tool developed within EU-ADR, which
searches Medline-indexed publications concerning adverse
drug reactions [30, 31], was used to qualify the drug–event
associations as ‘ADRs’ (i.e. already known to be true) or
‘non-ADRs’. For each drug–event association, Medline
citations with co-occurrence of the drug and the adverse
event of interest were extracted and manually reviewed by
two independent evaluators with experience in pharma-
covigilance and pharmacoepidemiology. For the list of
ADRs, we considered only those with at least three inde-
pendent PubMed citations that showed a potentially causal
association. The lowest level of evidence accepted was
CONFIRMED
5% random
sample check*
NOT CONFIRMED
YES
NO
Associaon
conﬁrmed
Associaon
NOT CONFIRMED
≥ 3 citaons
Verify drug-event associaon 
manually
Non-ADR
ADR
Class eﬀect
MANUAL CHECK Non-ADR
Query MEDLINE for each 
drug-event pair
Fig. 1 Workflow of verification of signals. *A 5 % random sample was manually checked to see if the classification as non–adverse drug
reactions (non-ADRs) was accurate
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three case reports mentioning the occurrence of a specific
adverse event in individual patients exposed to the specific
drug. Discrepancies in the assessment were resolved
through discussion. All associations for which not enough
evidence was found in the literature (i.e.\3 confirmatory
articles) were considered ‘non-ADRs’. For these, a random
sample of 5 % of drug–event associations for each of the
five events of interest was manually reviewed by the two
evaluators. In addition, if at least two drugs belonging to
the same therapeutic class (defined by having in common
the first five digits of their ATC codes) had a positive
association with a certain event, a class effect was sus-
pected and an additional manual review of the summary of
product characteristics (SmPC) was done to see if other
drugs in the class were also associated with that specific
event. Figure 1 shows a schematic workflow of the verifi-
cation process.
For the purposes of this study, drug–event associations
that were suggested to be ADRs according to the criteria
described above were assumed to be ADRs, otherwise
these associations were assumed to be non-ADRs.
2.6 Performance Indicators
In order to assess the complementarity of the systems and
to calculate the costs associated with identification of
potential signals from different sources, we used the fol-
lowing indicators:
Percentage of unilaterally identified signals is a varia-
tion of sensitivity (recall) metrics, which uses as the
numerator the number of true associations identified in one
system that were not identified in the other. We considered
this variable to be useful in quantifying the incremental
value of each system.
0% 20% 40% 60% 80% 100%
Cough And Cold Preparaons (n=31)
Antacids, Treatment Of Pepc Ulcer And
Flatulence (n=34)
Diurecs (n=37)
Cardiac Therapy (n=40)
Analgesics (n=40)
Anepilepcs (n=41)
Drugs Used In Diabetes (n=43)
Agents Acng On The Renin-Angiotensin System
(n=43)
Anthromboc Agents (n=50)
Anvirals For Systemic Use (n=52)
Psychoanalepcs (n=64)
Psycholepcs (n=76)
An-Asthmacs (n=77)
Aninﬂammatory And Anrheumac Products
(n=92)
Anbacterials For Systemic Use (n=135)
Percentage of potenal signals 
Eudravigilance Both EU ADRFig. 2 Distribution of potential
signals in the EudraVigilance
and (EU-ADR) databases,
grouped according to the
anatomical therapeutic chemical
(ATC) classification therapeutic
subgroup (note: only classes
with[30 potential signals are
shown)
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Sensitivity was calculated as the proportion of associa-
tions correctly identified by the method out of the total pool
of ADRs known to be true from the literature [32].
Number needed to detect (NND), originally described by
Hauben et al. [33] in the context of signal detection within
an SRS, was used as a proxy to express the costs associated
with each source of signals. This represents the number of
signals that would have to be reviewed to detect a single
signal that was proven to be true.
Spearman’s correlation coefficient (R value) was cal-
culated to determine whether there was a correlation
between the background incidence of the events and each
system’s capability to detect signals.
3 Results
From an initial dataset of 5536 drug–event associations
overall, 1490 potential signals (27 %) were flagged in
either EudraVigilance or EU-ADR (Fig. 2). Upon signal
verification, the ratio of ADRs to non-ADRs varied from
1:6 for acute pancreatitis to 1:19 for hip fracture.
The therapeutic classes comprising the majority of
potential signals identified in EudraVigilance were agents
acting on the renin–angiotensin system, antivirals for sys-
temic use and antithrombotic agents, while for EU-ADR
they were anti-asthmatics, psychoanaleptics and
antiepileptics (see Fig. 2). The percentages of potential
signals identified in both systems ranged from 2 to 24 %.
The median sensitivity for detecting signals across all
events in EudraVigilance was 42 % (range 20–71 %) and
for EU-ADR it was 27 % (range 23–60 %), with the values
depending on the event of interest (see Fig. 3). AMI was
the hardest to detect among all five events, with 65 % of
known AMI associations from the literature not being
flagged in either database system. Hip fracture and bullous
eruption seemed to be the easiest to identify overall, with
only 21 and 28 % of known associations remaining unde-
tected, respectively. From a system perspective, the most
easily identified events in the SRS were bullous eruption,
acute pancreatitis and UGIB, while in the EHR they were
hip fracture, UGIB and AMI.
The background incidence of the events, obtained from
EU-ADR, was plotted against the percentage of unilaterally
identified signals. The contribution of each database to
signal detection appeared to be correlated with the back-
ground incidence of the events, being positively although
non-significantly correlated in EU-ADR (R = 0.7,
P = 0.18) and inversely and significantly correlated in
EudraVigilance (R = -1, P\ 0.01) (see Fig. 4).
The associated costs were expressed as the number of
signals that would need to undergo review and further
investigation for one true safety issue to be identified. The
costs associated with detecting signals, expressed by
NNDs, were highly variable across events. With the
exception of bullous eruption, it seemed to be more ‘costly’
to detect safety signals in EU-ADR than in EudraVigilance,
with a median NND across all events of 7 versus 5. The
most ‘costly’ event in EudraVigilance was bullous eruption
(NND = 8), and the least ‘costly’ were UGIB and acute
pancreatitis (NND = 2). In EU-ADR, the most costly
signals to detect were those related to hip fracture
49 % 
26% 
26% 
19%
11%
22% 
16%
19% 
9.3% 
8.7% 
28 %
46% 
34% 
21% 
65% 
1.4% 
11%  
21%
51% 
16% 
BE (n=74)
PANC (n=140)
UGIB (n=98)
HIP FRACT (n=43)
AMI (n=103)
Eudravigilance % Common to both % Found in neither % EUADR %
Fig. 3 Contribution of each system to signal detection (i.e. percent-
age of ‘positive’ associations detected out of the total adverse drug
reaction [ADR] pool in the literature). ‘N’ indicates the total number
of true associations in the dataset, and ‘found in neither’ indicates that
the association was not highlighted as a signal in any of the databases
during the signal detection process. AMI acute myocardial infarction,
BE bullous eruption, EU-ADR exploring and understanding adverse
drug reactions, FRACT fracture, PANC pancreatitis, UGIB upper
gastrointestinal bleeding
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(NND = 9) and AMI (NND = 7), while the least costly
were those related to pancreatitis and bullous eruption
(NND = 3) (see Fig. 5).
4 Discussion
In this study, we aimed to investigate an additional value of
the EHR-based system for signal detection on top of the
traditional SRS. We focused on five different adverse
events deemed to be important in pharmacovigilance:
bullous eruption, AMI, acute pancreatitis, hip fracture and
UGIB.
Although EudraVigilance identified more signals overall
than EU-ADR—41 % of signals (187/458) compared with
32 % (147/458)—as previously shown in other studies
[16], this was not unexpected, considering that EudraVig-
ilance has worldwide coverage, whereas EU-ADR covers
only three countries. Furthermore, the EudraVigilance
system is primarily designed for signal detection.
Patadia et al. [16] performed a time-restricted analysis
(before and after a safety communication/media attention)
and showed that this has an impact on the numbers of
signals detected in both data sources in opposite ways
(i.e. an increase in the number of signals in the SRS after
media attention and a decrease in the EHR). While this
effect might partially explain our findings of higher sen-
sitivity for EudraVigilance, we consider it unlikely that it
entirely explains the difference, since the majority of sig-
nals that were tested did not attract media attention.
The capacity of EU-ADR and EudraVigilance to detect
signals was shown to differ depending on the nature of the
adverse event being investigated. The relatively poor
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performance of EudraVigilance in detecting hip fractures
and AMI might be due to the fact that both events are not
usually perceived as being drug induced and thus often fail
to be recognized and reported as ADRs, as has previously
been hypothesized [34]. The suspected ADRs documented
in an SRS such as EudraVigilance are highly dependent on
the reporter’s ability to recognize them as such, and some
characteristics are helpful in this respect: biological con-
cordance with the drug mechanism of action, a short time
to onset, a positive dechallenge and lack of alternative
causes. The adverse events that are not so obviously
attributed to drugs (because they are multifactorial), or that
already have a high background incidence, are likely to be
poorly captured by spontaneous reports [1, 3]. EHR-based
systems do not rely on reporter judgment; therefore, these
events may be better represented in such systems.
On the other hand, there is very low sensitivity for
detecting rare drug-induced events in EU-ADR, and this is
in line with previous research, which showed that, despite
the broad coverage of the EU-ADR network (around
20 million patients), there is simply not enough (statistical)
power to identify very rare events in the database [24].
Thus, for rare events that have drug treatment as their
primary aetiology, SRSs still seems to be the better solu-
tion so far. Our findings are consistent with those of Patadia
et al. [34], although different parameters were used to
determine the complementarity of the two systems.
We found a correlation between the background inci-
dence of the events and the contribution of each database to
signal detection; the correlation was statistically significant
for EudraVigilance but not for EU-ADR, possibly because
of the small number of events tested.
The burden associated with screening any data source
for signals depends on the number of signals that require
further assessment or investigation and the workload
involved in each of these investigations. The amount of
work needed to confirm or refute a signal is highly vari-
able, ranging from simple product information checks to
more complex analyses and formal pharmacoepidemio-
logical studies. In their study, Pizzoglio et al. [35] reported
a median time of 6 hours for initial assessment of a signal
(range 2–26 h). We did not collect similar information on
the time spent on assessment of the signals in our study,
since a semi-automatic method was used; however, we
considered the number of signals that needed further
investigation to be a reasonable proxy to express the
associated costs. We found that for all of the events (with
the exception of bullous eruption), it was more costly to
identify signals within the EHR-based system. However
there was a notable difference across the events as follows:
for hip fracture, where EU-ADR provided the most added
value, an 80 % increase in the cost per signal was observed
in comparison with detection in EudraVigilance. On the
other hand, for acute pancreatitis, the cost associated with
signal detection in EU-ADR was not much higher than that
in EudraVigilance; therefore, in this case, it may be justi-
fiable to use both systems. Because the two systems pro-
vided roughly the same contribution to detection of UGIB-
related signals, the value of supplementing SRSs with
EHR-based systems is probably dependent on the types of
drugs that can be captured in the particular EHR database.
Detecting AMI proved to be costly in both systems; how-
ever, the seriousness of the event, its public health impact
and the difficulty of detection might justify the extra cost of
using both an SRS and an EHR-based system. For bullous
eruption, because of the lack of an additional gain (only
one extra signal was identified), it might not be efficient to
use the EHR as a secondary signal source.
The range of events tested in this study, albeit carefully
selected, represented only a small sample of all possible
adverse events and therefore limits the external validity of
this research. The applicability of our findings to a broader
range of events will require further investigation. In addi-
tion, the overall background incidence of the events that
were selected was slightly skewed towards more common
events and, if our hypothesis holds true, this might have
resulted in a bias favouring EHR performance.
Another limitation was the retrospective nature of the
study: we actually tested the capacity of systems not to iden-
tify signals (i.e. new associations) but rather to detect already
identified safety issues. As Nore´n et al. [36] pointed out,
ideally the evaluation should be done using emerging safety
issues and not well-established ADRs. However, this is a
common limitation in signal detection research because of the
difficulties that accompany building a ‘reference standard’
and the long time needed to gather data prospectively.
Moreover, combining the two systems involved many
decisions regarding the choice of the signal detection
method and their implementation (e.g. the choice of
thresholds and precision estimates), which had a huge
impact on the results [37]. In addition, it was repeatedly
demonstrated that the aggregation level at which data
mining is performed influences the results [38, 39], and we
consider that the appropriate level is still an open question.
Nevertheless, the decision to use SMQs instead of pre-
ferred terms (PTs) may have had an impact on the results.
We acknowledge that use of different signal detection
methodologies and reference standards, as well as defini-
tions of events used in data mining, might lead to different
results. Therefore, our results might, to some extent, reflect
the relative strengths of each data source, but they would
also be influenced by the algorithms that were chosen.
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Although we acknowledge that the time to signal detection
is an important element to take into account, for this study
we focused primarily on other quantitative measures, such
as the number of signals and the number of false positives,
which are equally important.
This evaluation did not take into account the fact that an
EHR-based surveillance system would require additional
work for implementation and subsequent maintenance for
the purposes of signal detection (versus SRSs, which are
already established for such activities) and would thus
incur extra costs, which would be difficult to estimate.
Our study is one of the few studies performed so far that
have tried to explore how an SRS and an EHR-based
system might be used together with the aim of augmenting
drug safety surveillance. A previous study by Harpaz
et al. [12] had a similar aim but a different strategy, trying
to combine information from both data sources at a very
early stage in order to improve the ranking of signals by
replication of findings. In contrast, we explored scenarios
where use of EHRs can fill the gaps and add value to
already existing systems.
5 Conclusion
The more prudent goal in signal detection is identification
not of all signals but of the majority of signals in the most
efficient way—with the least time- and resource-consum-
ing approach. With this aim in mind, we showed that an
EHR-based system may complement an SRS in certain si-
tuations, especially in the presence of adverse events with a
high background incidence. While the SRS appeared to be
more cost effective overall, for some events that are very
hard to pick up, the costs associated with additional signal
detection in an EHR-based system may be justifiable.
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